Standout Papers

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation 2008 2026 2014 2020 6.5k
  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (2011)
    Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine
  2. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (2009)
    Lars Wallentin, Richard C. Becker et al. New England Journal of Medicine
  3. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial (2010)
    Lars Wallentin, Stefan James et al. The Lancet
  4. The Perioperative Management of Antithrombotic Therapy (2008)
    James D. Douketis, Peter B. Berger et al. CHEST Journal
  5. COVID-19 update: Covid-19-associated coagulopathy (2020)
    Richard C. Becker Journal of Thrombosis and Thrombolysis
  6. Platelet functions beyond hemostasis (2009)
    Susan S. Smyth, Rodger P. McEver et al. Journal of Thrombosis and Haemostasis
  7. Aptamers as Therapeutics (2017)
    Shahid M. Nimjee, Rebekah R. White et al. The Annual Review of Pharmacology and Toxicology
  8. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment (2011)
    Keith A.A. Fox, Jonathan P. Piccini et al. European Heart Journal
  9. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study (2010)
    Christopher P. Cannon, Robert A. Harrington et al. The Lancet
  10. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2014)
    Jonathan L. Halperin, Graeme J. Hankey et al. Circulation
  11. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium (2022)
    Diana A. Gorog, Robert F. Storey et al. Nature Reviews Cardiology

Immediate Impact

5 by Nobel laureates 7 from Science/Nature 141 standout
Sub-graph 1 of 15

Citing Papers

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
2021 Standout
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
2020 Standout
58 intermediate papers

Works of Richard C. Becker being referenced

Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes
2012
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
and 22 more

Author Peers

Author Last Decade Papers Cites
Richard C. Becker 21971 9096 5871 382 27.5k
Basil S. Lewis 18835 6722 6079 274 24.4k
Elaine M. Hylek 23759 10794 2612 252 30.2k
James E. Dalen 11661 6460 5183 203 18.1k
Stuart J. Connolly 42494 11551 4572 470 47.1k
Menno V. Huisman 15073 19427 5605 461 28.6k
David R. Anderson 8132 11730 5206 266 20.0k
Kurt Huber 21404 4537 9514 835 32.3k
Mark N. Levine 8778 12063 6569 317 30.6k
John W. Eikelboom 34233 18050 9081 653 46.1k
Martin H. Prins 17339 19486 8610 381 33.8k

All Works

Loading papers...

Rankless by CCL
2026